Drug ranking with zebrafish

Zeroshot Biolabs is building a platform that helps drug developers identify which compounds are most worth pursuing, reducing wasted time and cost in the discovery process. Instead of relying solely on human cell cultures, which often miss system-wide effects, Zeroshot uses young zebrafish as a whole-organism model. Zebrafish share the majority of human disease genes and organ systems, and their embryos can be tested rapidly and at scale.

Data from these standardized experiments feed into MegaFin, Zeroshot’s proprietary atlas of zebrafish responses, which powers its foundation AI model to predict how drugs move diseased cells toward healthier states.

‍